Search:

Exact Keyword


Total 605 results.
Sort by Relevant
U.S. Markets for Wound Dressings and Wound Cleansing/Debridement Products (2005)
192 Pages | 43 Exhibits | 2005 Analysis | Forecasts Through 2014 | Relavancy 1
In 2004, the U.S. market for wound dressings and wound cleansing/debridement products was valued at approximately $778 million. Over the forecast period covered by this report, sales are expected to increase at a compound annual rate of 5.5%, reaching approximately $1.3 billion in the year 2014. This market encompasses advanced wound dressings, chemical/enzymatic wound debridement products, nonocclusive dressings, and wound cleansing products. Factors contributing to growth in the wound dr...[Read More]




U.S. Markets for Compression Therapy and Pressure Reduction/Relief Products (2005)
158 Pages | 34 Exhibits | 2005 Analysis | Forecasts Through 2014 | Relavancy 1
In 2004, the U.S. market for compression therapy and pressure reduction/relief products was valued at approximately $1.1 billion. Over the forecast period covered by this report, sales are expected to increase at a compound annual rate of 3.8%, reaching approximately $1.6 billion in the year 2014. This market encompasses compression therapy products (e.g., compression bandages, compression stockings, and pneumatic compression therapy products) and pressure reduction/relief products (e.g., m...[Read More]




European Markets for Stents in Peripheral Vascular Applications (2005)
345 Pages | 109 Exhibits | 2005 Analysis | Forecasts Through 2011 | Relavancy 1
In 2004, the European peripheral vascular stents market was valued at approximately $306.1 million. Over the forecast period covered by this report, sales are expected to increase at a compound annual rate of 8.4%, reaching approximately $538.5 million in the year 2011. Market drivers include the aging of the population, improved screening and detection of peripheral vascular disease, technological advances, and a shift from lower-priced plastic stents to higher-priced metal stents. This...[Read More]




European Markets for Stents in Nonvascular Applications (2005)
238 Pages | 82 Exhibits | 2005 Analysis | Forecasts Through 2011 | Relavancy 1
In 2004, the European nonvascular stenting products market was valued at approximately $81.2 million. Over the forecast period covered by this report, sales are expected to increase at a compound annual rate of 5.1%, reaching approximately $114.4 million in the year 2011. Market drivers include the aging of the population, improved screening and detection of diseases, technological advances, and a shift from lower-priced plastic stents to higher-priced metal stents. This report from Med...[Read More]




U.S. Markets for Arthroscopy Products (2005)
162 Pages | 52 Exhibits | 2005 Analysis | Forecasts Through 2010 | Relavancy 1
Arthroscopy is defined as procedures which are performed using percutaneous instruments under the guidance of arthroscopes. The majority of arthroscopic procedures are performed on the knee (more than 1 million interventions and almost 2 million diagnoses each year). Repairing torn or damaged menisci of the knee is the most common arthroscopic treatment--the driving force in arthroscopy--with an estimated 875,000 annual meniscal repair procedures. Repair of torn anterior cruciate ligaments...[Read More]




U.S. Markets for Tissue-Engineered Skin Replacements/Substitutes and Active Wound Repair Modulators (2005)
145 Pages | 19 Exhibits | 2005 Analysis | Forecasts Through 2014 | Relavancy 1
Designed for use in burn and wound patients to either temporarily cover or permanently replace areas of missing skin, skin replacements and substitutes include allografts (made from donated human tissue); autografts (made from the patient's own tissue); dermal, epidermal, and multilayer human skin equivalents that may use autologous, donor, or synthetic materials for cell repopulation at the burn or wound site; as well as xenografts (made from animal tissue). Active wound repair modulators a...[Read More]




U.S. Markets for Interventional Cardiology Products (2005)
371 Pages | 99 Exhibits | 2005 Analysis | Forecasts Through 2009 | Relavancy 1
More adults in the U.S. die from cardiovascular diseases/disorders than from any other cause. Nationwide, approximately 70.1 million people have at least one cardiovascular condition; these diseases/disorders kill nearly 2,600 people in the U.S. each day, and result in direct and indirect costs that exceed $393.5 billion annually. In 2004, nearly 5.2 million diagnostic and therapeutic interventional cardiology procedures were performed in the U.S. These procedures generated more than ...[Read More]




U.S. Markets for Arrhythmia Management Products (2005)
305 Pages | 78 Exhibits | 2005 Analysis | Forecasts Through 2017 | Relavancy 1
Cardiac arrhythmias affect more than 5 million people nationwide, and result in more than 1.2 million hospitalizations and 400,000 deaths each year in the U.S. Arrhythmia management involves the use of a variety of products that enable clinicians to detect the presence of cardiac arrhythmias and determine their nature and extent, allowing the selection of appropriate treatment protocols, evaluation of chosen therapies, and establishment of patients' long-term prognoses. Products utilized...[Read More]




European Markets for Percutaneous Transluminal Coronary Angioplasty and Coronary Stenting Products (2005)
503 Pages | 231 Exhibits | 2005 Analysis | Forecasts Through 2011 | Relavancy 1
Coronary artery disease is the leading cause of death in Europe. The morbidity/mortality rates associated with the disease continue to fuel the demand for percutaneous transluminal coronary angioplasty (PTCA) and coronary stenting products--particularly drug-eluting stents--to treat advanced cases that cannot be adequately managed with medical therapy. Sales of PTCA products and coronary stents and stent systems in Europe reached approximately $1.4 billion in 2004. Growing at a healthy...[Read More]




U.S. Markets for Spinal Fusion Products (2005)
281 Pages | 33 Exhibits | 2005 Analysis | Forecasts Through 2009 | Relavancy 1
It is estimated that approximately 50 million people in the United States (U.S.) suffer from back pain. In 2004, more than 1 million spine surgeries were performed in the U.S.--far more than the number of hip and knee replacements combined. Factors driving growth of the spinal surgery products market include growing numbers of people with degenerative disc disease (DDD). DDD is typically caused by gradual disc damage and often results in disc herniation and chronic, debilitating lower bac...[Read More]




U.S. Markets for Ventilators, Oxygen Therapy Systems, and Airway Management Accessories (2005)
335 Pages | 94 Exhibits | 2005 Analysis | Forecasts Through 2010 | Relavancy 1
In the United States (U.S.) more than $1.3 billion was spent on ventilators, oxygen therapy systems, and airway management accessories in 2004. Growing at a healthy compound annual rate of 6.3%, sales of these products are expected to reach more than $1.9 billion by the year 2010. This dynamic report from Medtech Insight includes analyses of products and technologies, current and forecast markets, competitors, and opportunities in the U.S. ventilators market, as well as the oxygen therap...[Read More]




U.S. Markets for Diagnostic Imaging Systems (2005)
293 Pages | 41 Exhibits | 2005 Analysis | Forecasts Through 2009 | Relavancy 1
Diagnostic imaging systems, which enable clinicians to visualize the anatomic structure and evaluate the functional performance of the body\'s internal organs and tissues, are indispensable in the practice of modern medicine. In the United States, more than 300 million diagnostic imaging procedures--including angiography, conventional X-ray-based imaging, computed tomography, magnetic resonance imaging, nuclear medicine imaging, and ultrasound imaging--were performed in 2004. These proce...[Read More]




Opportunities in Heart Valve Disease Management: Europe, Japan and Rest of World (2005)
548 Pages | 147 Exhibits | 2005 Analysis | Forecasts Through | Relavancy 1
Although Europe and Japan have large, aging populations subject to degenerative heart conditions, and the developing nations continue to have sizeable populations with rheumatic heart disease, these individuals are much less likely to undergo surgical treatment of their valve disease than in the U.S. The highly invasive nature of valve surgery, high product costs, and the fact that, in many cases, heart valv...[Read More]




U.S. Opportunities in the Management of Urinary Incontinence (2005)
594 Pages | 177 Exhibits | 2005 Analysis | Forecasts Through | Relavancy 1
Recent epidemiological data indicate that urinary incontinence (UI) affects an astounding 34 million Americans, and 38 million are affected by overactive bladder (OAB). Roughly one-third of patients experience significant symptoms that may prompt them to seek treatment. Unfortunately, therapeutic options have been largely limited to the extremes of medical management or invasive surgery, creating significant undertreatment of this devastating, but not life-threatening condition. ...[Read More]




U.S. Markets for Cardiovascular Disease Diagnostic Products (2004)
382 Pages | 102 Exhibits | 2004 Analysis | Forecasts Through 2007 | Relavancy 1
More adults in the U.S. die from cardiovascular diseases/disorders than from any other cause. Nationwide, approximately 64.4 million people have at least one cardiovascular condition; these diseases/disorders kill nearly 2,600 people in the U.S. each day, and result in direct and indirect costs that exceed $368.0 billion annually. In 2003, more than 154.7 million electrocardiography, endovascular, noninvasive diagnostic imaging, and near patient in vitro testing procedures were performed...[Read More]




Emerging U.S. Markets for Myocardial Revascularization, Repair, and Regeneration Products and Technologies (2004)
324 Pages | 68 Exhibits | 2004 Analysis | Forecasts Through 2008 | Relavancy 1
In the United States (U.S.), cardiovascular disease afflicts more than a quarter of the population, causes more than 5 million hospitalizations, and claims nearly 1 million lives each year; additionally, more than $300 billion in healthcare expenditures are incurred annually. A major portion of these expenditures is associated with the management of the most prevalent acute and chronic myocardial conditions, such as debilitating drug-refractory angina pectoris, congestive heart failure, isch...[Read More]




European Markets for Orthopedic Implants and Trauma Products (2004)
416 Pages | 188 Exhibits | 2004 Analysis | Forecasts Through 2008 | Relavancy 1
The European orthopedic implants and trauma products market consists of reconstruction and replacement products for the hip, knee, shoulder, and small joints, as well as fracture fixation and bone growth stimulation products, bone graft substitutes and growth factors, and bone cements. In 2003, this market totaled more than $1.4 billion; key market drivers include surgeon acceptance of innovative technologies with medical-based evidence, orthopedic products receiving reimbursement code listi...[Read More]




U.S. Markets for Critical Care Patient Monitoring Products (2004)
195 Pages | 55 Exhibits | 2004 Analysis | Forecasts Through 2012 | Relavancy 1
Critical care units are the most expensive sites in the U.S. healthcare system, accounting for 30% to 40% of an acute care hospital's total budget. Despite the costs involved, critical care is one of the fastest-growing specialties in healthcare, as hospitals continue to assign an increasing proportion of their beds to patients with life-threatening conditions who require significant levels of monitoring and specialized care. Factors such as the growing acuity of hospital inpatients, th...[Read More]




U.S. Markets for Home Healthcare Products (2004)
300 Pages | 85 Exhibits | 2004 Analysis | Forecasts Through 2012 | Relavancy 1
The expense and reduced length of acute care hospital stays, the availability and evolution of new healthcare technologies, the aging of the U.S. population, and the fact that most patients prefer to be treated in their homes rather than in hospitals or skilled nursing facilities, are all driving forces in the expansion of the U.S. home healthcare products and services market. In addition to the services of home healthcare agencies, the home-based treatment of patients who are chronicall...[Read More]




U.S. Markets for Stroke Management Products (2004)
301 Pages | 65 Exhibits | 2004 Analysis | Forecasts Through 2008 | Relavancy 1
Stroke--a sudden and often catastrophic disruption in the delivery of oxygen and nutrients to the tissues of the brain--is the third-leading cause of death in the U.S., following heart disease and cancer. It is estimated that there will be 282,000 fatalities due to stroke in 2004, half of which will occur outside a hospital. Products used to manage stroke patients include diagnostic imaging systems, pharmaceuticals, and surgical and interventional systems. The U.S. market for these produ...[Read More]




Trends and Opportunities in U.S. Orthopedic Markets for Implant, Reconstruction, and Trauma Products (2004)
360 Pages | 96 Exhibits | 2004 Analysis | Forecasts Through 2012 | Relavancy 1
According to the American Academy of Orthopedic Surgeons, approximately 28.6 million people in the United States sustain some type of musculoskeletal injury annually, at a cost of approximately $254 billion. Many orthopedic reconstruction and trauma device manufacturers have experienced significant growth in the past several years. This robust growth is due to a number of factors including demographics and the aging population, improved technologies, and upward pricing of implants and devi...[Read More]




U.S. Markets for Critical Care Patient Management Products (2004)
414 Pages | 122 Exhibits | 2004 Analysis | Forecasts Through 2012 | Relavancy 1
Critical care units are the most expensive sites in the U.S. healthcare system, accounting for 30% to 40% of an acute care hospital's total budget. Despite the costs involved, critical care is one of the fastest-growing specialties in healthcare, as hospitals continue to assign an increasing proportion of their beds to patients with life-threatening conditions who require significant levels of monitoring and specialized care. Factors such as the growing acuity of hospital inpatients, th...[Read More]




U.S. Markets for General and Pelvic Endoscopic Surgery Products (2004)
418 Pages | 146 Exhibits | 2004 Analysis | Forecasts Through 2013 | Relavancy 1
In the U.S., more than 5 million general and pelvic endoscopic surgical procedures were performed in 2003. The advantages of endoscopic surgery over open surgery include lower overall treatment costs, reduced patient trauma, shorter hospital stays, and faster recovery times. These benefits have resulted in the conversion of many types of open surgery procedures to endoscopic procedures, a continuing trend that is being driven by advancements in the array of endoscopic surgery products that ...[Read More]




The U.S. Aesthetics Marketplace (2004)
181 Pages | 38 Exhibits | 2004 Analysis | Forecasts Through 2012 | Relavancy 1
In 2002, approximately 6.6 million people in the United States underwent cosmetic surgical and nonsurgical procedures, generating more than $861 million in associated product sales. Cosmetic procedures are rapidly gaining popularity among the baby boomer generation; as a result, sales are expected to experience a robust increase over the forecast period covered by this report. This report by Medtech Insight analyzes major market segments for aesthetic products, including topical aesthe...[Read More]




U.S. Opportunities in Heart Failure Technologies (2004)
560 Pages | 168 Exhibits | 2004 Analysis | Forecasts Through | Relavancy 1
Heart failure is a complex, clinical syndrome characterized by multiple causes, symptoms and presentations, but which continues to be managed almost exclusively by drug therapy. The large patient caseload (estimated at 5 million Americans and growing with demographics) coupled with the progressive nature of the disease, has generated substantial interest in new, device-based treatments, many of which are at ...[Read More]




U.S. Opportunities in the Management of Benign Uterine Conditions (2004)
305 Pages | 97 Exhibits | 2004 Analysis | Forecasts Through | Relavancy 1
Benign uterine conditions (predominantly fibroids, polyps, endometriosis, adenomyosis and menorrhagia) affect upwards of 25% of women of childbearing age in the U.S. Although most are asymptomatic, 2.6 million women seek medical treatment for these conditions annually. Therapy has traditionally relied on two extremes: medical management, comprising oral contraceptives, progestins and GnRH agonist...[Read More]




U.S. Opportunities in Osteoporosis Management (2004)
399 Pages | 116 Exhibits | 2004 Analysis | Forecasts Through | Relavancy 1
Osteoporosis affects an estimated 15 million Americans, predominantly postmenopausal women, with an additional 30 million considered at risk for the disease. Unfortunately, most patients are not diagnosed until they experience a fracture, as osteoporosis lacks distinct symptoms, had limited treatment options until recently, and is not considered a life-threatening condition. Thus, despite incre...[Read More]




U.S. Opportunities in Drug Delivery Technologies (2004)
814 Pages | 170 Exhibits | 2004 Analysis | Forecasts Through | Relavancy 1
The U.S. drug delivery market is entering a watershed period. Traditional infusion products will remain the mainstay of hospital-based healthcare; however, even with gains in implantable, insulin and disposable pumps, overall growth in this mature segment will be modest. In contrast, emerging, non-infusion drug delivery technologies are poised for significant growth as they enable the delivery ...[Read More]




Pharmacological and Device-Based Therapeutic Approaches to Breast Disease (2003)
443 Pages | 51 Exhibits | 2003 Analysis | Forecasts Through 2011 | Relavancy 1
In spite of major advances in early detection and adjuvant therapy, breast cancer, especially advanced-stage disease, remains a major clinical and human problem. There is an urgent need for new therapies and novel agents that are more effective than those currently available for the treatment of advanced breast cancer and will improve the survival rates and improve quality of life for patients. There are three principal approaches to the treatment of this disease: surgery, radiotherapy, an...[Read More]




Pharmacological and Device-Based Therapeutic Approaches to Cancer Management (2003)
361 Pages | 61 Exhibits | 2003 Analysis | Forecasts Through 2007 | Relavancy 1
In 2003, an estimated 1.3 million people in the U.S. will be diagnosed with cancer and 1 in 4 deaths will be due to the disease. In addition to the tragic human toll, the cost of fighting cancer exceeds $171 billion annually in the U.S.; of this, more than $12 billion is spent on sophisticated products to treat the disease and manage its complications and side effects. These products include anticancer drugs and biopharmaceuticals; radiotherapy and photodynamic therapy products, cryoablatio...[Read More]




Contact Us

Need help finding medtech research? Let us help you!